Literature DB >> 11265751

Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development.

E C Collins1, R Pannell, E M Simpson, A Forster, T H Rabbitts.   

Abstract

Chromosomal translocations are crucial events in the aetiology of many leukaemias, lymphomas and sarcomas, resulting in enforced oncogene expression or the creation of novel fusion genes. The study of the biological outcome of such events ideally requires recapitulation of the tissue specificity and timing of the chromosomal translocation itself. We have used the Cre-loxP system of phage P1 to induce de novo Mll-Af9 chromosomal recombination during mouse development. loxP sites were introduced into the Mll and Af9 genes on chromosomes 9 and 4, respectively, and mice carrying these alleles were crossed with mice expressing Cre recombinase. A resulting Mll-Af9 fusion gene was detected whose transcription and splicing were verified. Thus, programmed interchromosomal recombination can be achieved in mice. This approach should allow the design of mouse models of tumorigenesis with greater biological relevance than those available at present.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11265751      PMCID: PMC1084253          DOI: 10.1093/embo-reports/kvd021

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  18 in total

1.  A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.

Authors:  J L Pollock; P Westervelt; A K Kurichety; P G Pelicci; J L Grisolano; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.

Authors:  C L Dobson; A J Warren; R Pannell; A Forster; I Lavenir; J Corral; A J Smith; T H Rabbitts
Journal:  EMBO J       Date:  1999-07-01       Impact factor: 11.598

3.  A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination.

Authors:  A J Smith; M A De Sousa; B Kwabi-Addo; A Heppell-Parton; H Impey; P Rabbitts
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

4.  Transgenic mice for the preparation of hygromycin-resistant primary embryonic fibroblast feeder layers for embryonic stem cell selections.

Authors:  K A Johnson; C P Lerner; L C Di Lacio; P W Laird; A H Sharpe; E M Simpson
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

5.  Cre-mediated site-specific translocation between nonhomologous mouse chromosomes.

Authors:  J Van Deursen; M Fornerod; B Van Rees; G Grosveld
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

6.  A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells.

Authors:  F Schwenk; U Baron; K Rajewsky
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

Review 7.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

Review 8.  Chromosomal translocations in human cancer.

Authors:  T H Rabbitts
Journal:  Nature       Date:  1994-11-10       Impact factor: 49.962

9.  Altered Hox expression and segmental identity in Mll-mutant mice.

Authors:  B D Yu; J L Hess; S E Horning; G A Brown; S J Korsmeyer
Journal:  Nature       Date:  1995-11-30       Impact factor: 49.962

10.  An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.

Authors:  J Corral; I Lavenir; H Impey; A J Warren; A Forster; T A Larson; S Bell; A N McKenzie; G King; T H Rabbitts
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

View more
  38 in total

1.  Creating a transloxation. Engineering interchromosomal translocations in the mouse.

Authors:  G Testa; A F Stewart
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

Review 2.  Applications of the site-specific recombinase Cre to the study of genomic imprinting.

Authors:  Rosemary Oh-McGinnis; Meaghan J Jones; Louis Lefebvre
Journal:  Brief Funct Genomics       Date:  2010-07-02       Impact factor: 4.241

Review 3.  Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.

Authors:  Rajesh C Rao; Yali Dou
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

4.  Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.

Authors:  Lesley F Drynan; Richard Pannell; Alan Forster; Nicole M M Chan; Florencia Cano; Angelika Daser; Terence H Rabbitts
Journal:  EMBO J       Date:  2005-08-11       Impact factor: 11.598

Review 5.  Mouse chromosome engineering for modeling human disease.

Authors:  Louise van der Weyden; Allan Bradley
Journal:  Annu Rev Genomics Hum Genet       Date:  2006       Impact factor: 8.929

Review 6.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

Review 7.  Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective.

Authors:  Danilo Maddalo; Andrea Ventura
Journal:  Cancer Res       Date:  2016-08-12       Impact factor: 12.701

8.  Non-parallel recombination limits Cre-LoxP-based reporters as precise indicators of conditional genetic manipulation.

Authors:  Jing Liu; Spencer G Willet; Eric D Bankaitis; Yanwen Xu; Chris V E Wright; Guoqiang Gu
Journal:  Genesis       Date:  2013-03-26       Impact factor: 2.487

Review 9.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

10.  Efficient generation of long-distance conditional alleles using recombineering and a dual selection strategy in replicate plates.

Authors:  David Voehringer; Davina Wu; Hong-Erh Liang; Richard M Locksley
Journal:  BMC Biotechnol       Date:  2009-07-28       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.